Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Keytruda (pembrolizumab) is an immunotherapy drug used to treat many types of cancer. Your doctor will use imaging, blood tests, and other laboratory tests to monitor whether the drug is working.

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

MSD’s cancer immunotherapy, Keytruda, looks set to gain a lucrative first line lung cancer use in Europe, after regulators gave it the green light. Crucially, Keytruda (pembrolizumab ...

Keytruda has been approved since 2016 as a second ... HNSCC is Bristol-Myers Squibb's Opdivo (nivolumab), which can be used as a second-line option after chemotherapy. BMS' attempts to move ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.